4-HPR and FTI in Head and Neck Squamous Cell Carcinoma (HNSCC)

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2005
The primary objective of this study is to estimate the modulation of intermediate biological endpoints of the combination of 4-HPR and SCH66336, a farnesyl transferase inhibitor (FTI), across 4 randomly assigned dose levels in patients with locally advanced or recurrent head and neck cancer. We will also assess the activity, safety, tolerability and side effects of 4-HPR/SCH66336 and hope to establish a phase II regimen.
Epistemonikos ID: 951a906c1b9779e073fb274b8fcd5e86580cfafd
First added on: May 04, 2024